Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd. is an Indian multinational pharmaceutical company founded in 1983 and headquartered in Mumbai, India. It is publicly traded on the Bombay Stock Exchange (BSE: 524715) and the National Stock Exchange of India (NSE: SUNPHARMA). As the largest pharmaceutical company in India, Sun Pharma employs over 43,000 people globally and reported revenues of approximately $6.2 billion. The founding family, led by Managing Director Dilip Shanghvi, continues to hold a majority stake in the company.

Sun Pharma is a major operating company that manufactures and sells a wide range of pharmaceutical products in over 100 countries. Its portfolio includes Active Pharmaceutical Ingredients (APIs), generic and branded generic drugs, specialty products, and over-the-counter medications. The company's products cover numerous therapeutic areas, such as cardiology, psychiatry, neurology, dermatology, and oncology. Key markets include the United States and India, which together account for the majority of the company's revenue. Sun Pharma operates more than 40 manufacturing facilities across India, the U.S., Asia, Africa, Australia, and Europe.

Based on the provided data, Sun Pharmaceutical Industries is an operating company that has been a defendant in patent litigation. The company has been named as a defendant in two tracked cases in the U.S. District Court for the District of Delaware, a common venue for patent disputes, and has not appeared as a plaintiff. This defensive posture is typical for large generic and specialty pharmaceutical manufacturers that challenge patents held by brand-name drug companies.

The tracked cases, Veloxis Pharmaceuticals, Inc. v. Sun Pharmaceutical Industries Ltd., are examples of this dynamic. These lawsuits are Abbreviated New Drug Application (ANDA) cases, which occur when a generic drug manufacturer, like Sun Pharma, seeks FDA approval to market a generic version of a branded drug before the expiration of patents covering that drug. News reports indicate one of these disputes, concerning a generic version of Veloxis's drug Envarsus XR, was resolved through a settlement that blocked the generic's entry until May 2028.